Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
18191956
DOI
10.1016/j.neuropharm.2007.11.015
PII: S0028-3908(07)00375-9
Knihovny.cz E-resources
- MeSH
- Anticonvulsants therapeutic use MeSH
- Benzoates therapeutic use MeSH
- Time Factors MeSH
- Behavior, Animal drug effects MeSH
- Electroencephalography methods MeSH
- Fluoresceins MeSH
- Glycine analogs & derivatives therapeutic use MeSH
- Homocysteine analogs & derivatives MeSH
- Rats MeSH
- Drug Interactions MeSH
- Brain drug effects pathology MeSH
- Random Allocation MeSH
- Animals, Newborn MeSH
- Organic Chemicals MeSH
- Rats, Wistar MeSH
- Dose-Response Relationship, Drug MeSH
- Seizures chemically induced drug therapy pathology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 3,4-dicarboxyphenylglycine MeSH Browser
- Anticonvulsants MeSH
- Benzoates MeSH
- Fluoresceins MeSH
- fluoro jade MeSH Browser
- Glycine MeSH
- homocysteic acid MeSH Browser
- Homocysteine MeSH
- Organic Chemicals MeSH
The present study has examined the anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine ((S)-3,4-DCPG), a highly selective agonist for subtype 8 of group III metabotropic glutamate receptors (mGluRs), against seizures induced in immature 12-day-old rats by bilateral icv infusion of DL-homocysteic acid (DL-HCA, 600 nmol/side). For biochemical analyses, rat pups were sacrificed during generalized clonic-tonic seizures, approximately 45-50 min after infusion. Comparable time intervals were used for sacrificing the animals which had received (S)-3,4-DCPG (0.25 nmol/each side, 15-20 min prior to infusion of DL-HCA or saline). This agonist provided a pronounced anticonvulsant effect, generalized clonic-tonic seizures were completely suppressed and cortical energy metabolite changes which normally accompany these seizures were either normalized (decrease of glucose and glycogen) or markedly reduced (an accumulation of lactate). Anticonvulsant effect of (S)-3,4-DCPG was also evident from the EEG recordings, nevertheless, it was not complete. In spite of the absence of obvious motor phenomena, sporadic ictal activity could be seen in some animals. Isolated spikes could also be observed in some animals after administration of (S)-3,4-DCPG alone. The neuroprotective effect of (S)-3,4-DCPG was evaluated after 24 h and 6 days of survival following DL-HCA-induced seizures. Massive neuronal degeneration was observed in a number of brain regions following infusion of DL-HCA alone (seizure group), whereas pretreatment with (S)-3,4-DCPG provided substantial neuroprotection. The present findings suggest that receptor subtype 8 of group III mGluRs may be considered a promising target for drug therapy in childhood epilepsies in the future.
References provided by Crossref.org
Sulforaphane Ameliorates Metabolic Changes Associated With Status Epilepticus in Immature Rats